Literature DB >> 32585138

Use of aerosolised medications at home for COVID-19.

Arzu Ari1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32585138      PMCID： PMC7308028          DOI： 10.1016/S2213-2600(20)30270-8

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN： 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  8 in total

1.  Inhaled corticosteroids and the risk of pneumonia in people with asthma: a case-control study.

Authors:  Tricia McKeever; Timothy W Harrison; Richard Hubbard; Dominick Shaw
Journal:  Chest       Date:  2013-12       Impact factor: 9.410

2.  Inhaled corticosteroids and risk of upper respiratory tract infection in patients with asthma: a meta-analysis.

Authors:  Mingjin Yang; Yan Zhang; Hong Chen; Jiachen Lin; Jiatao Zeng; Zhibo Xu
Journal:  Infection       Date:  2018-10-08       Impact factor: 3.553

3.  Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?

Authors:  David M G Halpin; Rosa Faner; Oriol Sibila; Joan Ramon Badia; Alvar Agusti
Journal:  Lancet Respir Med       Date:  2020-04-03       Impact factor: 30.700

4.  Nebulisers as a potential source of airborne virus.

Authors:  Julian W Tang; Petri Kalliomaki; Taru M Varila; Matti Waris; Hannu Koskela
Journal:  J Infect       Date:  2020-05-15       Impact factor: 6.072

Review 5.  Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review.

Authors:  Khai Tran; Karen Cimon; Melissa Severn; Carmem L Pessoa-Silva; John Conly
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

6.  Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells.

Authors:  Mutsuo Yamaya; Hidekazu Nishimura; Xue Deng; Mitsuru Sugawara; Oshi Watanabe; Kazuhiro Nomura; Yoshitaka Shimotai; Haruki Momma; Masakazu Ichinose; Tetsuaki Kawase
Journal:  Respir Investig       Date:  2020-02-21

7.  Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1.

Authors:  Neeltje van Doremalen; Trenton Bushmaker; Dylan H Morris; Myndi G Holbrook; Amandine Gamble; Brandi N Williamson; Azaibi Tamin; Jennifer L Harcourt; Natalie J Thornburg; Susan I Gerber; James O Lloyd-Smith; Emmie de Wit; Vincent J Munster
Journal:  N Engl J Med       Date:  2020-03-17       Impact factor: 91.245

Review 8.  Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19.

Authors:  Arzu Ari
Journal:  Respir Med       Date:  2020-04-21       Impact factor: 4.582
  8 in total
  5 in total

Review 1.  The use of nebulized pharmacotherapies during the COVID-19 pandemic.

Authors:  Sanjay Sethi; Igor Z Barjaktarevic; Donald P Tashkin
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

Review 2.  Recent updates in COVID-19 with emphasis on inhalation therapeutics: Nanostructured and targeting systems.

Authors:  Ahmed A H Abdellatif; Hesham M Tawfeek; Ahmed Abdelfattah; Gaber El-Saber Batiha; Helal F Hetta
Journal:  J Drug Deliv Sci Technol       Date:  2021-02-19       Impact factor: 3.981

3.  Containment of procedure-associated aerosols by an extractor tent: effect on nebulized drug particle dispersal.

Authors:  M Fennelly; J Keane; L Dolan; B J Plant; D J O'Connor; J R Sodeau; M B Prentice
Journal:  J Hosp Infect       Date:  2021-01-20       Impact factor: 3.926

Review 4.  How to deliver aerosolized medications through high flow nasal cannula safely and effectively in the era of COVID-19 and beyond: A narrative review.

Authors:  Arzu Ari; Gerald B Moody
Journal:  Can J Respir Ther       Date:  2021-03-01

5.  Medication Cost-Savings and Utilization of Generic Inhaled Corticosteroid (ICS) and Long-Acting Beta-Agonist (LABA) Drug Products in the USA.

Authors:  Zhong Wang; Sharon K Ahluwalia; Bryan Newman; Sneha Dhapare; Liang Zhao; Markham C Luke
Journal:  Ther Innov Regul Sci       Date:  2022-02-03       Impact factor: 1.337
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.